Among the different antibody-based cancer therapies, antibodies are commonly employed which block signaling pathways that promote development of the pro-inflammatory TME, such as those against vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) (134). This evidence concerns the gene ERBB2 and cancer.